409 related articles for article (PubMed ID: 29637889)
1. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.
Greenaway C; Pareek M; Abou Chakra CN; Walji M; Makarenko I; Alabdulkarim B; Hogan C; McConnell T; Scarfo B; Christensen R; Tran A; Rowbotham N; van der Werf MJ; Noori T; Pottie K; Matteelli A; Zenner D; Morton RL
Euro Surveill; 2018 Apr; 23(14):. PubMed ID: 29637889
[TBL] [Abstract][Full Text] [Related]
2. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
Haukaas FS; Arnesen TM; Winje BA; Aas E
Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review.
Greenaway C; Pareek M; Abou Chakra CN; Walji M; Makarenko I; Alabdulkarim B; Hogan C; McConnell T; Scarfo B; Christensen R; Tran A; Rowbotham N; Noori T; van der Werf MJ; Pottie K; Matteelli A; Zenner D; Morton RL
Euro Surveill; 2018 Apr; 23(14):. PubMed ID: 29637888
[TBL] [Abstract][Full Text] [Related]
4. A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries.
Zammarchi L; Casadei G; Strohmeyer M; Bartalesi F; Liendo C; Matteelli A; Bonati M; Gotuzzo E; Bartoloni A;
BMC Health Serv Res; 2015 Sep; 15():412. PubMed ID: 26399233
[TBL] [Abstract][Full Text] [Related]
5. Modeling the Cost-Effectiveness of Latent Tuberculosis Screening and Treatment Strategies in Recent Migrants to a Low-Incidence Setting.
Dale KD; Abayawardana MJ; McBryde ES; Trauer JM; Carvalho N
Am J Epidemiol; 2022 Jan; 191(2):255-270. PubMed ID: 34017976
[TBL] [Abstract][Full Text] [Related]
6. Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020.
Margineanu I; Rustage K; Noori T; Zenner D; Greenaway C; Pareek M; Akkerman O; Hayward S; Friedland JS; Goletti D; Stienstra Y; Hargreaves S;
Euro Surveill; 2022 Mar; 27(12):. PubMed ID: 35332865
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection.
Zenner D; Hafezi H; Potter J; Capone S; Matteelli A
Int J Tuberc Lung Dis; 2017 Sep; 21(9):965-976. PubMed ID: 28826445
[TBL] [Abstract][Full Text] [Related]
8. Methodological considerations for economic modelling of latent tuberculous infection screening in migrants.
Shedrawy J; Siroka A; Oxlade O; Matteelli A; Lönnroth K
Int J Tuberc Lung Dis; 2017 Sep; 21(9):977-989. PubMed ID: 28826446
[TBL] [Abstract][Full Text] [Related]
9. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
[TBL] [Abstract][Full Text] [Related]
10. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal.
Sousa S; Rocha D; Silva JC; Ribeiro AI; Gonçalves G; Almeida Á; Correia AM; Duarte R; Carvalho C
Pulmonology; 2021; 27(6):493-499. PubMed ID: 34053903
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of tuberculosis screening for migrant children in a low-incidence country.
Usemann J; Ledergerber M; Fink G; Ritz N
Int J Tuberc Lung Dis; 2019 May; 23(5):579-586. PubMed ID: 31097066
[TBL] [Abstract][Full Text] [Related]
12. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study.
Abubakar I; Lalvani A; Southern J; Sitch A; Jackson C; Onyimadu O; Lipman M; Deeks JJ; Griffiths C; Bothamley G; Kon OM; Hayward A; Lord J; Drobniewski F
Health Technol Assess; 2018 Oct; 22(56):1-96. PubMed ID: 30334521
[TBL] [Abstract][Full Text] [Related]
13. Protocol for a cluster randomised control trial evaluating the efficacy and safety of treatment for latent tuberculosis infection in recent migrants within primary care: the CATAPuLT trial.
Burman M; Copas A; Zenner D; Hickson V; Gosce L; Trathen D; Ashcroft R; Martineau AR; Abubakar I; Griffiths C; Kunst H
BMC Public Health; 2019 Nov; 19(1):1598. PubMed ID: 31783742
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.
Steffen RE; Caetano R; Pinto M; Chaves D; Ferrari R; Bastos M; de Abreu ST; Menzies D; Trajman A
PLoS One; 2013; 8(4):e59546. PubMed ID: 23593145
[TBL] [Abstract][Full Text] [Related]
15. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.
Campbell JR; Johnston JC; Ronald LA; Sadatsafavi M; Balshaw RF; Cook VJ; Levin A; Marra F
Am J Kidney Dis; 2019 Jan; 73(1):39-50. PubMed ID: 30269868
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries.
Campbell JR; Johnston JC; Cook VJ; Sadatsafavi M; Elwood RK; Marra F
Emerg Infect Dis; 2019 Apr; 25(4):661-671. PubMed ID: 30882302
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional study of prevalence and risk factors, and a cost-effectiveness evaluation of screening and preventive treatment strategies for latent tuberculosis among migrants in Singapore.
Lim VW; Wee HL; Lee P; Lin Y; Tan YR; Tan MX; Lin LW; Yap P; Chee CB; Barkham T; Lee V; Chen M; Ong RT
BMJ Open; 2021 Jul; 11(7):e050629. PubMed ID: 34266845
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.
Diel R; Lampenius N; Nienhaus A
Pharmacoeconomics; 2015 Aug; 33(8):783-809. PubMed ID: 25774015
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
Tasillo A; Salomon JA; Trikalinos TA; Horsburgh CR; Marks SM; Linas BP
JAMA Intern Med; 2017 Dec; 177(12):1755-1764. PubMed ID: 29049814
[TBL] [Abstract][Full Text] [Related]
20. Screening for latent tuberculosis in migrants-status quo and future challenges.
Petersen E; Al-Abri S; Al-Jardani A; Memish ZA; Aklillu E; Ntoumi F; Mwaba P; Wejse C; Zumla A; Al-Yaquobi F
Int J Infect Dis; 2024 Apr; 141S():107002. PubMed ID: 38479577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
